Connected to Take Better Charge of Diabetes

Pictured: David, living with diabetes

We reach for our phone dozens of times a day. It connects us with people near and far, tracks our health, our physical activity and helps us organize our lives. This extends to the many apps we have at our fingertips that provide helpful information that make our daily tasks easier. For people living with diabetes, such apps can also provide helpful tools in the day-to-day management of their disease.

Making use of this ubiquitous connectivity and technology, Sanofi has recently partnered with two companies—French medical device maker Biocorp, and healthcare company and world leader in continuous glucose monitoringi  Abbott—to contribute to the development of a connected ecosystem. This incorporates connected devices that give people with diabetes access to information about their condition and improve the dialogue between a patient and their healthcare professional. The overall goal is to simplify people’s lives with tools that can be integrated into their daily routine while offering them more individualized care.

Diabetes can be overwhelming at times for patients using insulin as it involves frequent monitoring of glucose levels and adapting the insulin dose the body needs, while taking into account other factors, including variable carbohydrate consumption and physical activity. All this data comes from multiple sources and can at times be difficult to manage. 

Combining therapeutic options with smarter devices and services

One digital tool is a connected cap*, developed by Biocorp, that is designed to be attached to a range of Sanofi’s insulin pens, to help people with diabetes more easily track their insulin intake and link this with information from blood sugar meters via a dedicated mobile app. The data can also enable them and their healthcare team to see how treatment combined with lifestyle, diet and exercise can help them effectively manage their disease. 

biocorp

Sanofi’s collaboration with Abbott, announced last year, will be designed to enable data sharing between Abbott′s FreeStyle LibreLink mobile app and cloud software (LibreView), and Sanofi′s connected insulin pens, apps and cloud software, with the consent of the user, by connecting these digital tools that are currently in development.

“The overall package will give people living with diabetes much more access to information to better help them manage their condition,” said Chris Boulton, Head of Integrated Care, General Medicines, Sanofi. “This may help them to achieve better glucose control on a daily basis.” 

For almost a century, Sanofi has been at the forefront of the fight against diabetes, pioneering insulin-based treatments to help lower blood sugar levels. Today, that includes developing a connected ecosystem that aims to help people using insulins better monitor and manage their diabetes and live the life they want. 

*Availability of the connected cap and mobile app will depend on regulatory approvals in different countries.

More about diabetes

Diabetes is a complex disease caused by a deficiency and/or resistance to insulin, a hormone secreted by the pancreas. Type 1 (insulin-dependent) diabetes is an autoimmune disease that occurs when the immune system mistakenly attacks pancreatic cells that produce insulin and destroys them. It most often affects children and adolescents. Type 2 diabetes occurs when insulin produced by the body is insufficient to maintain blood sugar control. While these two main types of diabetes are different diseases, they are both characterized by an excess of sugar in the blood. They must be managed and treated effectively. In 2019, approximately 463 million adults worldwide were living with diabetes, a number that is set to jump to 700 million by 2045.1) 

Reference

1) https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html, last accessed February 2020

Related Links

woman
Diabetes Your Type

i Data on file, Abbott Diabetes Care.

For the U.S., click here for important safety information about FreeStyle Libre: https://www.freestylelibre.us/safety-information.html

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies
OK